MARKET

BLCM

BLCM

Bellicum Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.290
+0.190
+9.05%
After Hours: 2.310 +0.02 +0.87% 19:48 01/17 EST
OPEN
2.190
PREV CLOSE
2.100
HIGH
2.790
LOW
2.100
VOLUME
8.62M
TURNOVER
--
52 WEEK HIGH
4.140
52 WEEK LOW
0.7211
MARKET CAP
114.33M
P/E (TTM)
-0.9367
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BLCM and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

BLCM News

  • Mid-Morning Market Update: Markets Open Higher; Schlumberger Tops Q4 Views
  • Benzinga.1d ago
  • Bellicum Pharma Highlights Will Present New Translational Data For BPX-601 At ASCO 2020 Gastrointestinal Cancers Symposium Fri., Jan. 24, 2020
  • Benzinga.2d ago
  • Bellicum Pharmaceuticals to Present New Translational Data for BPX-601 at ASCO 2020 Gastrointestinal Cancers Symposium
  • GlobeNewswire.2d ago
  • PTLA, NKTR, SRNE and SIX among midday movers
  • Seeking Alpha - Article.01/10 17:43

More

Industry

Biotechnology & Medical Research
-0.16%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About BLCM

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
More

Webull offers Bellicum Pharmaceuticals Inc (BLCM) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.